MRF Breakthrough Consortium (MRFBC) Young Investigator Team Award to Advance the Field of Translational Immuno-Oncology Grant

MRF Breakthrough Consortium (MRFBC) Young Investigator Team Award to Advance the Field of Translational Immuno-Oncology Grant

Status: ACTIVE
Funder: Melanoma Research Foundation
Amount: Up to US $150,000
Last Updated: January 26, 2026

Summary

The MRFBC Young Investigator Team Award supports innovative research in immuno-oncology for melanoma, offering up to $150,000 annually for two years. This funding targets U.S.-based researchers aiming to enhance clinical outcomes for melanoma patients or deepen the scientific understanding of immuno-oncology. The MRF collaborates with key institutions to address challenges in melanoma research, fostering partnerships that maximize research potential and impact.

Overview

The MRFBC Team Award provides funding of up to $150,000 per year for two years to an investigative team whose research focuses on either improving clinical outcomes for patients with melanoma being treated with immuno‐oncology agents or advancing the scientific understanding of immuno‐oncology and the role of the immune system in melanoma. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges.

Eligibility

You can learn more about this opportunity by visiting the funder's website. U.S. based researchers from MRFBC institutionsU.S. based non-citizen researchers eligiblePostdoctoral fellows with less than five years of postdoctoral experience at the time the grant will be awardedResearch associates/ scientists, instructors, or assistant professors at the time of the grant submission.Researchers focused on improving clinical outcomes for melanoma patients being treated with immuno-oncology agentsResearchers analyzing the role of the immune system in melanoma.  Projects on cutaneous or rare subtypes of melanoma such as ocular, mucosal, 5 and/or pediatric melanoma

Ineligibility

Researchers based outside of the U.S